The first patient to receive a genetically modified porcine kidney survived 271 days without dialysis, then received a human kidney 82 days after removal of the animal graft, and that transplant functioned immediately. The study published in The Lancet by Massachusetts General Hospital suggests that a porcine kidney could serve as a bridge to a human allograft without clinically significant allosensitization in this patient. The question is no longer whether the technique works: it is how health systems will organize it, for whom, and at what cost.

The essentials

  • A porcine kidney provided 271 days of dialysis independence in the first treated patient, according to The Lancet (Massachusetts General Hospital, 2025).
  • After removal of the animal graft, a human transplant performed 82 days later functioned immediately, with no increase in anti-HLA antibodies during 231 days of follow-up.
  • This observation suggests different mechanisms of injury and supports further research, without by itself changing the clinical status of xenotransplantation.
  • This technique could eventually help address organ shortage, but its effect on waiting list mortality is not established by this study. According to HRSA data, approximately 17 people die each day in the United States waiting for an organ.
  • The challenge of the coming years: determining whether the technology becomes an accessible bridge or remains concentrated in a handful of academic centers.

13 deaths per day for lack of an available organ

In the United States, more than 100,000 patients are waiting for an organ of any type; the number of kidney transplant candidates is fewer than 100,000 according to available OPTN data. According to HRSA data, approximately 17 people die each day waiting for an organ. Dialysis keeps people alive, but it does not cure them. It costs approximately $90,000 per year per patient according to Medicare, a burden that weighs on the patient, their family, and the public system long before an organ becomes available.

This is why xenotransplantation, the transplant of an animal organ into a human, has long been presented as a distant promise. Early attempts with baboon hearts in the 1980s had failed. Rejections were swift. The human immune system recognized the animal organ as an invader and destroyed it within hours.

What changed is molecular biology. Companies specializing in genomic editing, including eGenesis and Revivicor, produced pigs whose cells have been modified to eliminate the most immunogenic porcine antigens and integrate human genes that make the organ more tolerable to the immune system. The pig became, in biological terms, somewhat less foreign.

271 days without dialysis: what the result proves

The publication concerns the first patient in a planned three-patient study. This is small in statistical terms, and the journal acknowledges this without ambiguity. But in medicine, well-documented clinical cases open pathways that randomized trials have not yet explored.

This patient, suffering from end-stage renal failure, received a genetically modified porcine kidney. The organ functioned for 271 days. During those nine months, he had no need for dialysis. The graft failed after immunosuppression reduction in the context of a non-zoonotic bacterial infection, with microvascular inflammation and thrombotic microangiopathy. A human kidney was transplanted 82 days later.

That kidney functioned immediately. The function of the allograft, associated with unchanged anti-HLA antibodies, showed no clinically significant allosensitization in this patient.

Anti-HLA antibodies, which measure this allosensitization, remained stable over 231 days of follow-up after the human transplant.

This is the result that shifts the debate. The hypothesis circulating in the transplant community was that prolonged exposure to an animal organ could create antibodies that would then make a human transplant more difficult. This study did not detect clinically significant allosensitization in this patient under the conditions observed. It does not resolve the question for all patients under all conditions, but it gives clinical teams solid proof of concept on which to build larger trials.

Long-term immunological follow-up remains the critical point: the late-onset injury observed could involve mechanisms beyond conventional antibody-mediated rejection.

The therapeutic bridge, a new clinical category

Until now, debates on xenotransplantation revolved around a binary question: can porcine transplant permanently replace human transplant? This framing created a fictional competition between two interventions that could actually complement each other.

The MGH study suggests a different architecture. A patient on the waiting list whose condition is deteriorating could receive a porcine kidney as a bridge to a future human transplant. In this case, the porcine kidney served as a bridge to a human transplant while also remaining studied as a possible long-term alternative strategy.

This bridge logic also transforms the profile of potentially eligible patients. Today, clinical trials of xenotransplantation often target patients in critical condition, for whom no other option exists. This is understandable from an ethical and regulatory standpoint—we start with those for whom the benefit-risk ratio is most favorable. But if the goal is to reduce waiting list mortality, potentially eligible patients for a therapeutic bridge would include those whose condition is deteriorating while awaiting transplant.

This distinction has concrete implications for access rules. Primary care prevents a large share of cardiac hospitalizations by intervening early in patients’ trajectories; the same principle should guide integration of xenotransplantation: intervene before deterioration, not after.

The decisions awaiting health systems

A proof of concept in an elite academic center becomes a public health tool only if three conditions are met: clear access rules, defined funding, and shared data.

On funding, the calculation is more favorable than it appears. Dialysis costs approximately $90,000 per year in the United States. Over five years, costs cannot be estimated with a fixed amount without specifying the year, the modality, coverage, and the care categories included. A rigorous economic evaluation of the complete cost of xenotransplantation compared to prolonged dialysis remains necessary. This evaluation has yet to be done rigorously, by health economists independent of companies developing the grafts.

On data, the challenge is structural. Xenotransplantation generates specific infectious risks; pigs carry endogenous retroviruses (PERV) whose transmission to humans remains theoretically possible. American guidelines recommend lifelong clinical follow-up and virological surveillance adapted to infectious risk. This follow-up is burdensome, expensive, and depends on centers’ ability to maintain contact with patients over decades. Without a centralized public registry, these data risk remaining scattered among teams and companies, which will slow collective learning.

The pancreatic organoid biobank illustrates how a shared data infrastructure can accelerate precision medicine; the same model applies here, with even broader stakes.

Three trajectories for 2030

Renal xenotransplantation stands today at a crossroads whose outcome depends on collective decisions, not just scientific ones. Several trajectories are possible.

The first is the standard bridge. Five patients had received the EGEN-2784 product under expanded access in the United States; a planned American trial for 33 patients had not yet begun. If these trials confirm the MGH results and if regulatory authorities grant approval for use as a therapeutic bridge, xenotransplantation could potentially be integrated into transplantation protocols. Patients facing long waiting times would be the first beneficiaries. This trajectory assumes that public systems, Medicare in the United States, health insurance in Europe, accept reimbursement for the procedure, which is not guaranteed.

The second trajectory is specialized niche. Late immunological complications could limit the use of xenotransplantation to specific protocols. This scenario would not be a scientific failure, but a narrow success: a technique useful for certain patient profiles, under very particular conditions, without measurable impact on overall waiting list mortality.

The third trajectory is the most concerning: concentrated access. Expensive xenotransplantation dependent on the resources of large academic centers risks concentrating access, reproducing the historical inequalities observed in transplantation. Rates of kidney transplantation have historically varied substantially by geographic area, and Black or African American patients have historically encountered inequalities in access to listing and waiting time for kidney transplant. Nothing guarantees that xenotransplantation will escape these biases.

The signals to monitor to distinguish these trajectories are specific: the median duration of dialysis independence in upcoming trials (beyond a single patient), the rate of anti-HLA allosensitization after graft removal in larger cohorts, and the survival of human transplants performed after xenotransplantation. If these indicators remain solid across several dozen patients, the first trajectory becomes most likely. If they worsen, the second becomes inevitable.

Immediate obligations for regulators and clinicians

Research advances quickly. Institutions, more slowly. The gap between the two is the main risk of this period.

Three collective needs are already identifiable. First, a public registry for long-term follow-up: data on survival, rejection, infection, and immune allosensitization must be accessible to researchers and regulators, not just to companies developing the grafts. Second, patient selection criteria made public before enlarged trials open, so that access decisions are based on transparent medical criteria, not financial capacity or geographic proximity to a center. Finally, an independent economic evaluation of the complete cost per year of dialysis avoided, which permits public decision-makers to place xenotransplantation in an honest comparison with existing alternatives.

The FDA has already published preliminary guidelines on xenotransplantation trials. The European Medicines Agency (EMA) has a framework for xenogeneic cellular products, but not necessarily guidance equivalent to the FDA’s for whole-organ xenotransplantation. This regulatory asymmetry could lead to faster trials in the United States and delayed access in Europe, or trials conducted where regulation is less stringent, which would weaken data quality.

Renal xenotransplantation shows, in this case, that it provided prolonged renal support before a subsequent human allograft without detected allosensitization. The coming years will tell whether health systems will know how to integrate it as a common tool or will let it become another privilege.


Sources

  1. Massachusetts General Hospital / The Lancet, Clinical study on porcine renal xenotransplantation (2025)
  2. PubMed, Supplementary study on long-term immunological follow-up of porcine grafts (2025)
  3. UNOS (United Network for Organ Sharing), Data on kidney waiting list and mortality while awaiting organ
  4. Centers for Medicare & Medicaid Services (CMS), Data on annual cost of dialysis for Medicare patients
  5. FDA, Preliminary guidelines on clinical trials for xenotransplantation